274 related articles for article (PubMed ID: 20423238)
1. Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs.
Slaby O; Sachlova M; Bednarikova M; Fabian P; Svoboda M; Vytopilova S; Valik D; Vyzula R
Cancer Biother Radiopharm; 2010 Apr; 25(2):237-43. PubMed ID: 20423238
[TBL] [Abstract][Full Text] [Related]
2. Distribution and functional significance of somatostatin receptors in malignant melanoma.
Lum SS; Fletcher WS; O'Dorisio MS; Nance RW; Pommier RF; Caprara M
World J Surg; 2001 Apr; 25(4):407-12. PubMed ID: 11344389
[TBL] [Abstract][Full Text] [Related]
3. Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy.
Ćwikła JB; Bodei L; Kolasinska-Ćwikła A; Sankowski A; Modlin IM; Kidd M
J Clin Endocrinol Metab; 2015 Nov; 100(11):E1437-45. PubMed ID: 26348352
[TBL] [Abstract][Full Text] [Related]
4. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
[TBL] [Abstract][Full Text] [Related]
5. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas.
Taboada GF; Luque RM; Bastos W; Guimarães RF; Marcondes JB; Chimelli LM; Fontes R; Mata PJ; Filho PN; Carvalho DP; Kineman RD; Gadelha MR
Eur J Endocrinol; 2007 Jan; 156(1):65-74. PubMed ID: 17218727
[TBL] [Abstract][Full Text] [Related]
6. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR.
Taboada GF; Luque RM; Neto LV; Machado Ede O; Sbaffi BC; Domingues RC; Marcondes JB; Chimelli LM; Fontes R; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
Eur J Endocrinol; 2008 Mar; 158(3):295-303. PubMed ID: 18299461
[TBL] [Abstract][Full Text] [Related]
7. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.
Cives M; Kunz PL; Morse B; Coppola D; Schell MJ; Campos T; Nguyen PT; Nandoskar P; Khandelwal V; Strosberg JR
Endocr Relat Cancer; 2015 Feb; 22(1):1-9. PubMed ID: 25376618
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life.
Faggiano A; Carratù AC; Guadagno E; Tafuto S; Tatangelo F; Riccardi F; Mocerino C; Palmieri G; Damiano V; Siciliano R; Leo S; Mauro A; Tozzi LF; Battista C; De Rosa G; Colao A
Oncotarget; 2016 Feb; 7(5):5538-47. PubMed ID: 26701729
[TBL] [Abstract][Full Text] [Related]
9. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.
Kubota A; Yamada Y; Kagimoto S; Shimatsu A; Imamura M; Tsuda K; Imura H; Seino S; Seino Y
J Clin Invest; 1994 Mar; 93(3):1321-5. PubMed ID: 8132773
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.
Strosberg JR; Yao JC; Bajetta E; Aout M; Bakker B; Hainsworth JD; Ruszniewski PB; Van Cutsem E; Öberg K; Pavel ME
Endocr Relat Cancer; 2015 Dec; 22(6):933-40. PubMed ID: 26373569
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.
Shojamanesh H; Gibril F; Louie A; Ojeaburu JV; Bashir S; Abou-Saif A; Jensen RT
Cancer; 2002 Jan; 94(2):331-43. PubMed ID: 11900219
[TBL] [Abstract][Full Text] [Related]
12. High-administered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of neuroendocrine tumors: preliminary experience.
Kong G; Johnston V; Ramdave S; Lau E; Rischin D; Hicks RJ
Cancer Biother Radiopharm; 2009 Oct; 24(5):527-33. PubMed ID: 19877882
[TBL] [Abstract][Full Text] [Related]
13. Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment.
Casarini AP; Jallad RS; Pinto EM; Soares IC; Nonogaki S; Giannella-Neto D; Musolino NR; Alves VA; Bronstein MD
Pituitary; 2009; 12(4):297-303. PubMed ID: 19330452
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptor subtype gene expression in pituitary adenomas.
Miller GM; Alexander JM; Bikkal HA; Katznelson L; Zervas NT; Klibanski A
J Clin Endocrinol Metab; 1995 Apr; 80(4):1386-92. PubMed ID: 7714115
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
[TBL] [Abstract][Full Text] [Related]
16. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
17. Gene expression of somatostatin receptor subtypes SSTR2a, SSTR3 and SSTR5 in peripheral blood of neuroendocrine lung cancer affected patients.
Muscarella LA; D'Alessandro V; la Torre A; Copetti M; De Cata A; Parrella P; Sperandeo M; Pellegrini F; Frusciante V; Maiello E; Merla G; Fazio VM; Vendemiale G
Cell Oncol (Dordr); 2011 Oct; 34(5):435-41. PubMed ID: 21503779
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1--5 and correlation with receptor protein expression and tumor pathology.
Kumar U; Grigorakis SI; Watt HL; Sasi R; Snell L; Watson P; Chaudhari S
Breast Cancer Res Treat; 2005 Jul; 92(2):175-86. PubMed ID: 15986128
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment.
Janson ET; Oberg K
Cancer Chemother Biol Response Modif; 2003; 21():535-46. PubMed ID: 15338762
[No Abstract] [Full Text] [Related]
20. SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors.
Pisarek H; Pawlikowski M; Kunert-Radek J; Kubiak R; Winczyk K
Folia Histochem Cytobiol; 2010 Jan; 48(1):142-7. PubMed ID: 20529830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
